Test Price
2,800 AED✅ Home Collection Available
RUNX1 Gene Mutation Test for Acute Myeloid Leukemia (AML) – NGS Genetic Test in Dubai | 2800 AED
Executive Summary & Core Metrics
- Accuracy Assurance: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
- Regulatory Compliance: Full adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The RUNX1 Genetic Test identifies germline and somatic mutations in the RUNX1 gene associated with acute myeloid leukemia (AML) and familial platelet disorder with predisposition to myeloid malignancies. This test is essential for accurate diagnosis, risk stratification, and guiding targeted therapy decisions. Using Next-Generation Sequencing (NGS), the assay provides full gene coverage to detect novel and known variants with high sensitivity.
| Feature | Our Test (NGS) | Sanger Sequencing (Closest Alternative) |
|---|---|---|
| Precision | Full gene coverage, detects novel variants | Targeted exon analysis, limited to known mutations |
| Method | Next-Generation Sequencing (NGS) | Capillary Electrophoresis Sanger |
| Turnaround Time | 3–4 Weeks (comprehensive analysis) | 2–3 Weeks (per gene region) |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that identifying RUNX1 mutations provides critical information for tailored therapy and family planning. However, these results must be integrated with comprehensive clinical evaluation. Always consult your hematologist for treatment decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory & Safety Protocols
This genetic test is a diagnostic adjunct and does not replace emergency clinical evaluation. Do not discontinue any prescribed medications, especially anticoagulants, without consulting your doctor. Results should be reviewed in the context of a full medical history and current clinical status.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or sepsis – postpone non-urgent genetic testing.
- Uncontrolled bleeding or platelet count <20×10⁹/L – phlebotomy risk assessed by clinician.
- Acute promyelocytic leukemia (APL) symptoms (e.g., sudden bruising, coagulopathy) – seek immediate emergency care.
- New neurological deficits or signs of leukostasis (visual changes, hypoxia) – immediate ER visit required.
- Pregnancy – discuss risk-benefit with maternal-fetal medicine specialist before sample collection.
Patient FAQ & Clinical Guidance
1. What is the purpose of the RUNX1 gene test in leukemia?
The RUNX1 Genetic Test identifies mutations linked to acute myeloid leukemia to guide diagnosis, prognosis, and familial risk assessment. It distinguishes between sporadic and inherited forms, helping tailor chemotherapy protocols and hematopoietic stem cell transplant decisions. Results are interpreted by a board-certified hematopathologist for clinical correlation.
2. How should I prepare for the blood collection?
No fasting or medication changes are required; routine DNA extraction from whole blood or FTA card is unaffected by meals. Inform the phlebotomist of all anticoagulants, but never stop prescribed therapy without medical advice. Our VIP mobile phlebotomy team ensures a stress-free home draw with strict cold-chain transport to the laboratory.
3. When will I receive results and how are they delivered?
The full NGS report, reviewed by our consultant medical geneticist, is issued within 3 to 4 weeks in a secure, DHA-compliant electronic format. You will receive a telephonic consultation to interpret the findings and understand the implications for your treatment or family screening. Urgent preliminary results can be expedited for active clinical decision-making upon request.
UAE Regulatory & Data Privacy Adherence
This test and all associated data processing comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. All patient information is handled under strict confidentiality and stored in accordance with DHA guidelines. Our laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | RUNX1 Gene Mutation Test for Acute Myeloid Leukemia (AML) – NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (VIP Mobile Phlebotomy & Cold-Chain Home Collection available) or Formalin-Fixed Paraffin-Embedded (FFPE) tissue block (Secure Medical Courier Retrieval) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full gene coverage |
| ICD-10-CM Code | C92.00 – Acute myeloid leukemia, not having achieved remission; D46.9 – Myelodysplastic syndrome, unspecified; Z15.02 – Genetic susceptibility to malignant neoplasm of hematopoietic & lymphoid tissue |
| LOINC Code | 81256-4 – RUNX1 gene mutations found in Blood or Tissue by Sequencing |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians